Back to Newsroom

Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140

BERKELEY HEIGHTS, N.J., April 04, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the presentation of preclinical data outlining the potential therapeutic utility of CYC140, a polo-like kinase (PLK) 1 inhibitor, for the treatment of esophageal cancer and acute leukemia. The findings were presented during the American Academy of Cancer Research (AACR) Annual Meeting, April 1-5, in Washington, D.C.

Click here to read the full release